Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Alexandre Mérieux, Ryan Taft, Robert Darnell

Premium

Alexandre Mérieux has assumed the role of CEO at BioMérieux. He previously was a deputy chief executive officer and corporate vice president of microbiology unit and manufacturing and supply operations at the company.


Ryan Taft has joined Illumina as director of scientific research.

Taft is laboratory head and senior research fellow at the University of Queensland's Institute for Molecular Bioscience. He holds a BSc in biochemistry and molecular biology from the University of California, Davis. Taft will maintain a joint appointment with UQ while working for Illumina.


Robert Darnell has been elected to the National Academy of Sciences. Darnell is president, CEO, and scientific director of the New York Genome Center. He is also a senior physician at the Rockefeller University Hospital and an adjunct attending neuro-oncologist at the Memorial Sloan-Kettering Cancer Center. Previously, he was the Heilbrunn Professor at the Rockefeller University and a Howard Hughes Institute Investigator.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.